bromocriptine has been researched along with cyclin d1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Q; Li, Z; Liang, J; Liu, Z; Shao, Z; Song, C; Wang, X; Xiao, Z; Yang, X; Zhang, K | 1 |
| Li, Z; Liu, Z; Shao, Z; Song, C; Wang, X; Xiao, Z; Yang, X; Zhang, K | 1 |
2 other study(ies) available for bromocriptine and cyclin d1
| Article | Year |
|---|---|
Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Topics: Animals; bcl-X Protein; Bromocriptine; Cell Line, Tumor; Cyclin D1; Humans; Mice; Mice, Nude; Pimozide; Pituitary Neoplasms; Prolactinoma; Rats; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Hypophysectomy; Male; MAP Kinase Signaling System; Middle Aged; Neoplasm Recurrence, Local; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Receptors, Prolactin; Young Adult | 2020 |